Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-014498
Filing Date
2023-08-10
Accepted
2023-08-10 16:06:04
Documents
67
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rain-20230630x10q.htm   iXBRL 10-Q 1476175
2 EX-31.1 rain-20230630xex31d1.htm EX-31.1 13752
3 EX-31.2 rain-20230630xex31d2.htm EX-31.2 17831
4 EX-32.1 rain-20230630xex32d1.htm EX-32.1 12770
  Complete submission text file 0001558370-23-014498.txt   6818696

Data Files

Seq Description Document Type Size
5 EX-101.SCH rain-20230630.xsd EX-101.SCH 47859
6 EX-101.CAL rain-20230630_cal.xml EX-101.CAL 55071
7 EX-101.DEF rain-20230630_def.xml EX-101.DEF 156255
8 EX-101.LAB rain-20230630_lab.xml EX-101.LAB 460366
9 EX-101.PRE rain-20230630_pre.xml EX-101.PRE 317158
61 EXTRACTED XBRL INSTANCE DOCUMENT rain-20230630x10q_htm.xml XML 1301542
Mailing Address 8000 JARVIS AVENUE SUITE 204 NEWARK CA 94560
Business Address 8000 JARVIS AVENUE SUITE 204 NEWARK CA 94560 (510) 953-5559
Rain Oncology Inc. (Filer) CIK: 0001724979 (see all company filings)

EIN.: 821130967 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40356 | Film No.: 231159297
SIC: 2834 Pharmaceutical Preparations